Table 4.
Summary of GRADE on evidences of primary outcomes.
| References | Certainty assessment | No. of patients | Effect | Certainty | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No.of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Trial | Control | Relative (95% CI) | Absolute (95% CI) | |||
| UPDRS I SCORES | |||||||||||||
| Wang et al. (2012) | 5 | R | Serious | Not serious | Not serious | Not serious | None | 178 | 173 | – | MD 0.33 lower (0.58 lower to 0.08 lower) |
⊕⊕⊕○ Moderate |
Important |
| Zhang et al. (2015) | 9 | R | Serious | Not serious | Not serious | Not serious | None | 374 | 416 | – | MD 0.68 higher (0.38 higher to 0.98 higher) |
⊕⊕⊕○ Moderate |
Important |
| Wei et al. (2017) | 2 | R | Not serious | Not serious | Not serious | Not serious | None | 80 | 80 | – | MD 0.40 lower (0.71 lower to 0.09 lower) |
⊕⊕⊕⊕ High |
Important |
| Shan et al. (2018) | 4 | R | Not serious | Not serious | Not serious | Not serious | None | 218 | 182 | – | MD 0.30 lower (0.54 lower to 0.06 lower) |
⊕⊕⊕⊕ High |
Important |
| UPDRS II SCORES | |||||||||||||
| Wang et al. (2012) | 9 | R | Serious | Not serious | Not serious | Not serious | None | 395 | 391 | – | MD 2.18 lower (3.03 lower to 1.33 lower) |
⊕⊕⊕○ Moderate |
Important |
| Zhang et al. (2015) | 12 | R | Serious | Not serious | Not serious | Not serious | None | 524 | 566 | – | MD 2.14 higher (1.66 higher to 2.62 higher) |
⊕⊕⊕○ Moderate |
Important |
| Wei et al. (2017) | 5 | R | Not serious | Not serious | Not serious | Not serious | None | 168 | 164 | – | MD 0.47 lower (0.69 lower to 0.25 lower) |
⊕⊕⊕⊕ High |
Important |
| Shan et al. (2018) | 7 | R | Not serious | Not serious | Not serious | Not serious | None | 346 | 311 | – | MD 2.21 lower (3.19 lower to 1.22 lower) |
⊕⊕⊕⊕ High |
Important |
| UPDRS III SCORES | |||||||||||||
| Wang et al. (2012) | 12 | R | Serious | Serious | Not serious | Not serious | None | 522 | 511 | – | MD 2.35 lower (4.61 lower to 0.08 lower) |
⊕⊕○○ Low |
Important |
| Zhang et al. (2015) | 14 | R | Serious | Not serious | Not serious | Not serious | None | 639 | 682 | – | MD 2.45 higher (2.03 higher to 2.86 higher) |
⊕⊕⊕○ Moderate |
Important |
| Wei et al. (2017) | 5 | R | Not serious | Serious | Not serious | Not serious | None | 168 | 164 | – | MD 0.35 lower (0.57 lower to 0.13 lower) |
⊕⊕⊕⊕ High |
Important |
| Shan et al. (2018) | 8 | R | Not serious | Serious | Not serious | Not serious | None | 386 | 350 | – | MD 3.26 lower (4.36 lower to 2.16 lower) |
⊕⊕⊕⊕ High |
Important |
| UPDRS IV SCORES | |||||||||||||
| Wang et al. (2012) | 7 | R | Serious | Not serious | Not serious | Not serious | None | 238 | 236 | – | MD 0.51 lower (0.83 lower to 0.20 lower) |
⊕⊕⊕○ Moderate |
Important |
| Zhang et al. (2015) | 10 | R | Serious | Not serious | Not serious | Not serious | None | 362 | 406 | – | MD 0.32 higher (0.15 higher to 0.49 higher) |
⊕⊕⊕○ Moderate |
Important |
| Wei et al. (2017) | 3 | R | Not serious | Not serious | Not serious | Not serious | None | 94 | 97 | – | MD 0.32 lower (0.60 lower to 0.03 lower) |
⊕⊕⊕⊕ High |
Important |
| Shan et al. (2018) | 5 | R | Not serious | Not serious | Not serious | Not serious | None | 240 | 207 | – | MD 0.18 lower (0.37 lower to 0.01 higher) |
⊕⊕⊕⊕ High |
Important |
| THE TOTAL SCORE OF UPDRS | |||||||||||||
| Wang et al. (2012) | 10 | R | Serious | Not serious | Not serious | Not serious | None | 382 | 367 | – | MD 60.9 lower (8.08 lower to 4.10 lower) |
⊕⊕⊕○ Moderate |
Important |
| Zhang et al. (2014) | 4 | R | Serious | Not serious | Not serious | Not serious | None | 129 | 128 | – | MD 7.35 lower (11.24 lower to 3.47 lower) |
⊕⊕⊕○ Moderate |
Important |
| Zhang et al. (2015) | 10 | R | Serious | Not serious | Not serious | Not serious | None | 386 | 414 | – | MD 6.18 higher (5.06 higher to 7.31 higher) |
⊕⊕⊕○ Moderate |
Important |
| Wei et al. (2017) | 7 | R | Not serious | Not serious | Not serious | Not serious | None | 282 | 276 | – | MD 0.35 lower (0.53 lower to 0.20 lower) |
⊕⊕⊕⊕ High |
Important |
| Shan et al. (2018) | 10 | R | Not serious | Not serious | Not serious | Not serious | None | 269 | 234 | – | MD 5.43 lower (8.01 lower to 2.86 lower) |
⊕⊕⊕⊕ High |
Important |
| PDQ-39 | |||||||||||||
| Wei et al. (2017) | 4 | R | Not serious | Not serious | Not serious | Not serious | None | 141 | 141 | – | MD 0.35 lower (0.59 lower to 0.12 lower) |
⊕⊕⊕⊕ High |
Important |
| Shan et al. (2018) | 3 | R | Not serious | Not serious | Not serious | Not serious | None | 91 | 92 | – | MD 7.65 lower (11.46 lower to 3.83 lower) |
⊕⊕⊕⊕ High |
Important |
| NMSQUEST | |||||||||||||
| Shan et al. (2018) | 2 | R | Not serious | Not serious | Not serious | Not serious | None | 74 | 73 | – | MD 9.19 lower (13.11 lower to 5.28 lower) |
⊕⊕⊕⊕ High |
Important |
GRADE, Grade of Recommendation, Assessment, Development, and Evaluation; R: randomized trials; PDQ-39, Parkinson's Disease Questionnaire-39; NMSQuest, Non-Motor Symptoms Questionnaire; CHM, Chinese herbal medicine; CWM, Conventional western medicine.